Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00903266|
Recruitment Status : Suspended (Covid-19 Pandemie)
First Posted : May 18, 2009
Last Update Posted : May 19, 2020
|Condition or disease||Intervention/treatment||Phase|
|Aphasia Stroke Cerebrovascular Accident Apoplexy Cerebral Infarction||Behavioral: Melodic Intonation Therapy Behavioral: Speech-Repetition-Therapy||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Behavioral and Neural Correlates of Melodic-Intonation-Therapy (MIT) and Speech-Repetition-Therapy (SRT) for Patients With Non-fluent Aphasia|
|Study Start Date :||February 2008|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||June 2020|
Melodic Intonation Therapy
Behavioral: Melodic Intonation Therapy
MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
Active Comparator: SRT
Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
No Intervention: NTC
No-Therapy Control; Patients in this arm will be re-randomized to the two active arms at the end of the NTC period.
- Correct Information Units (CIU)/min and CIUs/phrase elicited during spontaneous speech [ Time Frame: Baseline (x2), midpoint of therapy, end of therapy, 4 weeks after end of therapy ]
- 1) Items named on a standard picture naming test; 2) timed automatic speech; 3) linguistically-based measures of phrase and sentence analysis; 4) functional and structural imaging measures [ Time Frame: baseline (x2), midpoint of therapy, end of therapy, 4 weeks after end of therapy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00903266
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center / Harvard Medical School|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Gottfried Schlaug, MD, PhD||Beth Israel Deaconess Medical Center / Harvard Medical School|
|Study Director:||Andrea Norton, BM||Beth Israel Deaconess Medical Center|